Trump Announces Major Tariffs on Imported Medicines

In a significant shift in trade and healthcare policy, the administration of Donald Trump has announced plans to impose tariffs of up to 100% on select imported medicines. The move is aimed at encouraging pharmaceutical companies to shift manufacturing operations to the United States, but it also raises concerns about global supply chains and drug affordability.

The decision reflects a broader protectionist push, with the administration increasingly using trade tools to strengthen domestic production and reduce reliance on foreign suppliers.

Key Details of the New Tariff Policy

Who Will Be Affected?

The new tariffs will primarily target patented or branded medicines produced in countries that do not have trade agreements with the US. Additionally, companies that have not entered into most-favored-nation (MFN) pricing agreements with the government will face higher duties.

Timeline for Implementation

• Larger pharmaceutical companies will face tariffs within 120 days
• Smaller manufacturers will get a longer window of 180 days before the levies apply

This staggered rollout is intended to give companies time to adjust their operations or negotiate with the administration.

Tariff Rates and Exemptions Explained

Reduced Tariffs for Allied Nations

Imports from major economies that have trade agreements with the US will face a capped tariff rate of 15%. These include:

• European Union
• South Korea
• Japan
• Switzerland
• Liechtenstein

Imports from the United Kingdom will be subject to an even lower rate.

Incentives for Domestic Manufacturing

Pharmaceutical companies that commit to partial manufacturing within the US will benefit from reduced tariffs:

• 20% tariff for companies with some US production
• 0% tariff for companies that enter MFN pricing agreements

The tariff-free exemption under MFN agreements will remain valid until January 20, 2029.

Impact on Pharmaceutical Companies

Large Drugmakers Avoid Major Hit

Many global pharmaceutical giants, including Merck & Co. and Eli Lilly & Co., have already negotiated agreements with the administration. These deals reportedly include:

• Lower drug prices for Medicaid programs
• Direct sales models for US consumers
• Launching drugs at prices comparable to other developed nations

As a result, these companies are largely shielded from the harshest tariffs.

Smaller Firms Bear the Brunt

The new policy is expected to disproportionately affect smaller pharmaceutical companies and ingredient manufacturers, which may lack the resources to shift production or negotiate favorable terms.

What About Generic Medicines?

Generic drugs have been excluded from the current round of tariffs. However, the administration has directed the Commerce Department to reassess this exemption within one year. This leaves open the possibility that generic medicines could face tariffs in the future, depending on domestic production levels.

Legal and Policy Background

The tariffs stem from an investigation launched in April 2025 under the Section 232 of the Trade Expansion Act. This provision allows the president to impose tariffs on imports deemed a threat to national security.

This move follows a recent setback for Trump’s trade agenda after the Supreme Court of the United States ruled in February that certain global tariffs violated the Constitution. However, tariffs under Section 232 remain unaffected by that ruling.

Economic and Healthcare Implications

Supply Chain Disruptions

Industry experts warn that the tariffs could disrupt global pharmaceutical supply chains, potentially leading to:

• Drug shortages
• Increased production costs
• Delays in new drug availability

Rising Costs for Consumers

Pharmaceutical companies now face a critical decision:

• Absorb the tariff costs
• Or pass them on to consumers

Given that the US already has the highest drug prices globally, the latter could further strain patients financially.

Will Patients Feel the Impact Immediately?

The impact on consumers may not be immediate due to the complex pricing structure of the US healthcare system. Drug prices are determined through negotiations involving:

• Insurance companies
• Pharmacy benefit managers
• Drug manufacturers

However, over time, patients could face higher out-of-pocket costs, including increased co-pays and insurance premiums.

Trump’s Broader Trade Strategy

This policy is part of Trump’s long-standing stance that foreign dependence in critical sectors like pharmaceuticals poses a national security risk. He has previously suggested tariffs of up to 200% to force companies to bring manufacturing back to the US.

While several companies have already announced multibillion-dollar investments in US facilities, the administration has proceeded with tariffs to accelerate this transition.

Conclusion

The decision to impose up to 100% tariffs on certain imported medicines marks a major escalation in US trade policy and reflects a growing emphasis on domestic manufacturing. While the move may strengthen local production in the long term, it also introduces significant challenges for the global pharmaceutical industry.

Smaller companies are likely to face the greatest pressure, while consumers could eventually bear the financial burden through higher drug prices. Although exemptions and negotiated agreements may soften the immediate impact, the broader implications for supply chains, healthcare affordability, and international trade remain uncertain.

As the policy unfolds, its success will depend on whether it can balance national security goals with the need to maintain affordable and accessible healthcare for millions of Americans.